IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 3 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $142,388 | +2.4% | 31,294 | +58.4% | 0.00% | -100.0% |
| Q2 2023 | $139,047 | +8.5% | 19,751 | -5.9% | 0.00% | – |
| Q1 2023 | $128,212 | -13.5% | 20,984 | -9.5% | 0.00% | – |
| Q4 2022 | $148,197 | -17.7% | 23,192 | +23.5% | 0.00% | – |
| Q3 2022 | $180,000 | -10.9% | 18,782 | +2.5% | 0.00% | -100.0% |
| Q2 2022 | $202,000 | -9.8% | 18,324 | +36.1% | 0.00% | – |
| Q1 2022 | $224,000 | -10.4% | 13,468 | +2.8% | 0.00% | -100.0% |
| Q4 2021 | $250,000 | -38.9% | 13,099 | -21.1% | 0.00% | 0.0% |
| Q3 2021 | $409,000 | -5.8% | 16,600 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $434,000 | +9.0% | 16,679 | +32.7% | 0.00% | 0.0% |
| Q1 2021 | $398,000 | -31.0% | 12,568 | +1.1% | 0.00% | -50.0% |
| Q4 2020 | $577,000 | +9.3% | 12,432 | -22.5% | 0.00% | 0.0% |
| Q3 2020 | $528,000 | +21.1% | 16,034 | +0.9% | 0.00% | 0.0% |
| Q2 2020 | $436,000 | +43.9% | 15,896 | +57.2% | 0.00% | 0.0% |
| Q1 2020 | $303,000 | – | 10,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 3,876,600 | $127,618,000 | 11.48% |
| Fairmount Funds Management LLC | 596,890 | $19,650,000 | 8.32% |
| Ghost Tree Capital, LLC | 575,000 | $18,929,000 | 5.47% |
| Perceptive Advisors | 10,085,632 | $332,019,000 | 4.85% |
| Avoro Capital Advisors LLC | 9,536,039 | $313,926,000 | 4.46% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $43,224,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 315,000 | $10,370,000 | 2.82% |
| Orbimed Advisors | 6,645,100 | $218,757,000 | 2.75% |
| QVT Financial LP | 572,971 | $18,862,000 | 2.30% |
| Prosight Management, LP | 120,606 | $3,970,000 | 1.89% |